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Abstract: A wireless powered implantable atrial defibrillator consisting of a battery driven 
hand-held radio frequency (RF) power transmitter (ex vivo) and a passive (battery free) 
implantable power receiver (in vivo) that enables measurement of the intracardiac 
impedance (ICI) during internal atrial defibrillation is reported. The architecture is  
designed to operate in two modes: Cardiac sense mode (power-up, measure the impedance 
of the cardiac substrate and communicate data to the ex vivo power transmitter) and cardiac 
shock mode (delivery of a synchronised very low tilt rectilinear electrical shock 
waveform). An initial prototype was implemented and tested. In low-power (sense) mode, 
>5 W was delivered across a 2.5 cm air-skin gap to facilitate measurement of the 
impedance of the cardiac substrate. In high-power (shock) mode, >180 W (delivered as a 
12 ms monophasic very-low-tilt-rectilinear (M-VLTR) or as a 12 ms biphasic very-low-tilt-
rectilinear (B-VLTR) chronosymmetric (6ms/6ms) amplitude asymmetric (negative phase 
at 50% magnitude) shock was reliably and repeatedly delivered across the same interface; 
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with >47% DC-to-DC (direct current to direct current) power transfer efficiency at a 
switching frequency of 185 kHz achieved. In an initial trial of the RF architecture 
developed, 30 patients with AF were randomised to therapy with an RF generated  
M-VLTR or B-VLTR shock using a step-up voltage protocol (50–300 V). Mean energy for 
successful cardioversion was 8.51 J ± 3.16 J. Subsequent analysis revealed that all patients 
who cardioverted exhibited a significant decrease in ICI between the first and third shocks 
(5.00 Ω (SD(σ) = 1.62 Ω), p < 0.01) while spectral analysis across frequency also  
revealed a significant variation in the impedance-amplitude-spectrum-area (IAMSA) 
within the same patient group (|∆(IAMSAS1-IAMSAS3)[1 Hz − 20 kHz] = 20.82 Ω-Hz  
(SD(σ) = 10.77 Ω-Hz), p < 0.01); both trends being absent in all patients that failed to 
cardiovert. Efficient transcutaneous power transfer and sensing of ICI during cardioversion 
are evidenced as key to the advancement of low-energy atrial defibrillation. 
Keywords: wireless; battery-free; implantable; impedance; RF; defibrillator 
 
1. Introduction 
Atrial fibrillation (AF) is one of the most common cardiac arrhythmias observed in medicine. It is 
caused by rapid unsynchronised contractions that give rise to “quivering” of the upper atria. This 
results in a partial loss of cardiac output. Clinically, atrial fibrillation is the breakdown of synchronised 
electrical activity in the upper chamber of the heart and is diagnosed on an electrocardiogram (ECG) as 
a small fluctuating baseline undulation of variable magnitude and morphology at a rate of 
approximately 350–600 beats/min [1]. Fundamentally, atrial fibrillation is associated with deterioration 
in cardiac function and increased risk of stroke resulting in significant morbidity and mortality. The 
most recently published data from the Rotterdam study reports a 5.5% prevalence of AF in individuals 
over the age of 55 years while AF is currently estimated to account for 30%–40% of all 
hospitalizations due to cardiac arrhythmias. AF is estimated to affect an estimated 4.5 million people in 
Europe and 3.0 million adults in the United States; with numbers expected to double over the next 25 
years and associated treatment costs currently estimated at in excess of 15.7 billion US dollars per 
annum within Europe alone. The need for improved and more efficacious therapies therefore remains 
self evident [2–5]. 
For AF patients where pharmacological intervention is either deemed inappropriate or has failed, 
external electrical cardioversion (the delivery of asynchronized direct current shockacross the patient’s 
chest in an attempt to restore sinus rhythm) is often used. However, high energy shocks of up to 200 J 
(typically delivered as a monophasic or biphasic electrical impulse measuring up to 2.5 kV for 12 ms 
in duration) are required for successful transthoracic cardioversion; giving rise to extreme patient 
discomfort and necessitating heavy sedation or full anesthesia. Moreover, this method often fails; most 
commonly in large patients where thoracic impedance is high. This has led to the development of 
synchronised internal atrial defibrillation (more commonly referred to as internal cardioversion), a 
procedure which employs either a single or pair of electrically conductive catheters to deliver an 
electrical shock directly between the distal coronary sinus and the right atrial appendage of the heart in 
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an attempt to restore sinus rhythm. Internal cardioversion of atrial fibrillation has been shown to be 
effective and safe in a number of clinical studies. In particular, it continues to have a role in the 
treatment of patients who have previously been unsuccessfully treated using direct current 
transthoracic cardioversion. After internal cardioversion, the long-term outcome in a patient’s 
refractory to external cardioversion is good; especially if total arrhythmia duration has been brief [6,7]. 
Moreover, one of the primary advantages of internal cardioversion is that the energy required for a 
successful outcome (more commonly referred to as the defibrillation threshold) is substantially 
reduced; typically by up to a factor of ten (to <20 J). However, the fact remains that synchronised 
internal cardioversion still necessitates patient sedation and is an invasive procedure with all of the 
attendant risks of tissue damage, infection and the potential to induce other cardiac arrhythmias. 
The potential use of implantable devices for patients with AF has therefore received a great deal of 
attention. In 1995, the first human implant of a stand-alone implantable atrial defibrillator (IAD) took 
place. The battery-powered device detected AF and delivered R-wave synchronous defibrillation 12 ms 
biphasic shocks (chronosymmetric 6ms/6ms) at maximum of 300 V to convert AF to sinus rhythm [8–10]. 
However, the use of IAD’s for the treatment of AF has not yet achieved critical acceptance; 
predominately due to the impact of unit automaticity on the patients quality of life and the lack of 
patient tolerance to the discomfort produced by high energy shocks [11,12]. Recent publications 
indicate that the further advancement of internal cardioversion for AF may therefore result from two 
specific lines of enquiry: (i) optimisation of the defibrillation shock impulse to achieve the lowest 
energy necessary to successfully cardiovert a patient (less than 1 J could potentially negate the need for 
patient sedation) and (ii) investigation of passive (battery free) implantable atrial defibrillators that can 
facilitate AF arrhythmia detection and cardioversion under controlled circumstance in a non-acute care 
(out-of-hospital) setting [13–25]. In respect of the optimisation of electrical shock waveforms to 
achieve a defibrillation threshold of <1 J, transthoracic impedance (TTI) is a key determinant in the 
success of both atrial and ventricular defibrillation; due to the fact that cardioversion outcome highly 
correlates to the current vector delivered to the cardiac substrate. Hence, modern external defibrillators 
first measure the impedance of the cardiac substrate before delivering a precise amount of energy using 
an impedance compensated biphasic (ICB) shock waveform. In several studies, biphasic and biphasic 
impedance compensated defibrillators have been found to be more effective than equivalent high 
energy monophasic devices [14–17]. However, there remains a paucity of studies examining the 
correlation of the intracardiac impedance (DC impedance, dynamic impedance and waveform spectral 
content) during internal atrial defibrillation to clinical outcomes. In addition, recent publications have 
indicated that multiple low energy intracardiac shocks may give rise to lower cardioversion  
thresholds [18–23] thereby significantly minimising patient discomfort. Yet again, a paucity of studies 
comparing the efficaciousness of such protocols exists. In respect of the potential for passive (battery 
free) implantable defibrillator technologies to enable treatment in a non-acute care setting, the concept 
has several obvious merits; the issue of implant automaticity and inappropriate shocks is resolved 
(thereby addressing the potential quality of life associated issues previously identified) while the need 
for repeat surgery to replace batteries over the lifetime of the patient is entirely eliminated. 
Consequently, low-energy cardioversion using passive implantable defibrillator technology offers the 
potential for the development of AF treatment modalities and protocols that could be safely delivered 
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in a non-acute (out-of-hospital) care setting; thereby eliminating the need for repeated hospitalisation 
and significantly reducing the long term cost burden associated with treatment [20,25]. 
In this paper we propose and demonstrate a wireless powered implantable atrial defibrillator 
architecture that enables capture of the intracardiac impedance between successive shocks during the 
internal cardioversion procedure; thereby enabling implementation of impedance compensated internal 
atrial defibrillation therapies that are optimized to each individual patient and that could potentially be 
delivered in a non-acute care (out-of-hospital) setting. An initial trial of the RF architecture developed 
has successfully demonstrated cardioversion at low-energy and also revealed heretofore unreported 
observations that intracardiac impedance measurements captured during low-energy cardioversion 
contain markers in both the time and frequency domain that correlate to low-energy cardioversion 
outcome. Efficient transcutaneous power transfer, wireless powered in vivo sensing and measurement 
of intracardiac impedance during cardioversion are therefore evidenced as key to the advancement of  
low-energy defibrillation therapies. 
2. Methods 
2.1. Experimental Design 
Figure 1 shows a top-level schematic of the power transmitter (ex vivo) and power receiver (in vivo) 
architecture while Figure 2 provides an image of one of the prototypes developed. The hand-held 
external power transmitter consists of a microcontroller based unit that contains a tuned parallel RLC 
resonant tank circuit energized via a capacitor array (three 680 µF 400 V electrolytic capacitors 
managed by a LT375I charge controller) and driven via synchronous switching of an IGBT 
(IRG4PH40U) located in the current return path to ground from the primary coil (LT = 9.65 µH:  
30 turn spiral coil, inner diameter 20 mm, 0.75 mm insulated copper wire) with resonant capacitor  
(CT = 10 nF). Similarly, the implantable power receiver consists of a series RLC resonant tank circuit 
with a primary-secondary turns ratio of 1:1 (LR = 9.65 µH: 30 turn spiral coil, inner diameter 20 mm, 
0.75 mm insulated copper wire) and a resonant capacitor (CR = 10 nF) wired in a central tapped 
configuration that drives a full-wave voltage double circuit; with multiple regulators to provide the 
range of voltages (6–18 V) required for operation of the integrated control, measurement and 
communications circuitry. Both circuits (Tx/Rx) were designed for operation at approximately  
185 kHz. The output of the receiver coil is then rectified and filtered. Several linear regulators provide 
the necessary range of voltages (18 V, 12 V and 6 V) required for successful operation of the control, 
measurement and data communications circuitry on the implant side. The implantable power receiver 
unit contains a low-power integrated microcontroller (FRDM-KL25ZARM processor) that 
communicates with the base unit and coordinates between two distinct modes of operation: cardiac 
sense mode (wake-up, measure the impedance of the cardiac substrate and communicate data to the 
external base unit) and shock mode (delivery of an ECG synchronised impedance compensated 
monophasic very-low-tilt-rectilinear shock waveform). In low-power or sense mode, >5 W of power is 
continuously transferred while receiver temperature monitoring ensures that maximum implant 
operating temperatures are never exceeded. In this mode, a modified Howland bridge is used to  
non-destructively determine the impedance spectrum of the cardiac substrate by injecting a sinusoidal 
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test current of fixed magnitude (±98 μA) and measuring the voltage response across a range of 
frequencies (1–20 kHz). This measurement can then be sent via a dedicated communications link (433 
MHz) to the external base unit. This dual-band architecture facilitates independent optimisation of both 
the power transfer and data-communications links. In the shock delivery mode, an ECG synchronised 
impedance compensated M-VLTR shock waveform (100 V at 50 Ω for 12 ms) can then be delivered to 
the cardiac substrate via atrial leads attached to the implanted coil. Several initial prototypes were 
developed including variants incorporating H-Bridge reversal circuitry to facilitate delivery of 
monophasic or biphasic shock waveforms. 
 
Figure 1. Top-level implantable transcutaneous RF power link architecture. 
 
Figure 2. Prototype hand-held (ex vivo) radio frequency (RF) power-transmitter and 
prototype battery-free implantable (in vivo) power-receiver (encapsulated for bench 
characterisation). 
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2.2. Simulation and Characterisation 
Theoretical analysis and simulation of the RF architecture developed (Figure 1) was approached as 
previously reported [24]. Analysis was complicated by the fact that the receiver rectifier circuit 
effectively takes on a different configuration dependent on the type of waveform being delivered to the 
patient (monophasic (positive only) or biphasic (with a negative phase component)). In order to 
approach calculation and estimation of the RF link efficiency, a simplified circuit topology was 
adopted. Figure 3a shows the actual receiver architecture while Figure 3b shows the simplified model 
developed; which comprehends the parasitic series resistance for both the transmitter and receiver coils 
but ignores the associated distributed capacitance. 
 
Figure 3. (a) Implantable receiver architecture and (b) simplified circuit used for analysis. 
This parallel-series resonant tank configuration may be modelled as a current-in/current-out 
topology and effectively provides current and voltage magnification in the transmitter (parallel 
resonance) and receiver (series resonance), respectively. The impedance of the receiver ZRX and the 
transmitter ZTX circuit can therefore be expressed as: 
𝑍𝑅𝑥 = (𝑅𝑅 + 𝑅𝐿) + 𝑗 (𝜔 ∙ 𝐿𝑅 −
1
𝜔 ∙ 𝐶𝑅
) (1) 
𝑍𝑇𝑥 =
𝑅𝑇 + 𝑅𝑅𝐸𝐹 + 𝑗 ∙ 𝜔 ∙ 𝐿𝑇
1 + (𝑅𝑇 + 𝑅𝑅𝐸𝐹)𝑗 ∙ 𝜔 ∙ 𝐶𝑇 = 𝜔2 ∙ 𝐶𝑇 ∙ 𝐿𝑇
 (2) 
from which the reflected impedance ZREF  from the receiver to the transmitter circuit may be derived as: 
Sensors 2015, 15 22384 
 
 
𝑍𝑅𝐸𝐹 =  
𝜔2 ∙ 𝑀2(𝑅𝑅 + 𝑅𝐿)
(𝑅𝑅 + 𝑅𝐿)2 + (𝜔 ∙ 𝐿𝑅 −
1
𝜔∙𝐶𝑅
)
2 + 𝑗 [−
𝜔2 ∙ 𝑀2 (𝜔 ∙ 𝐿𝑅 −
1
𝜔∙𝐶𝑅
)
(𝑅𝑅 + 𝑅𝐿)2 + (𝜔 ∙ 𝐿𝑅 −
1
𝜔∙𝐶𝑅
)
2] (3) 
where LT and LR are the self-inductance values for the transmitter and receiver windings, respectively, 
RT and RR are the parasitic series resistance shown for each coil, respectively, M is the mutual 
inductance between coils, ω represents the angular frequency and RL is the load resistance. Further 
analysis resolves the receiver and transmitter resonance capacitor values CR and CT as:  
𝐶𝑅 =
1
𝜔0
2 ∙ 𝐿𝑅
 (4) 
𝐶𝑇 =
𝐿𝑇
𝜔2 ∙ 𝐿𝑇
2 + (𝑅𝑇 + 𝑅𝑅𝐸𝐹)
 (5) 
from which the link efficiency (η) is defined as the product between the transmitter (ηT) and receiver 
(ηR) circuit efficiencies where: 
𝜂(𝑇) =
𝑃𝑅
𝑃𝑇𝑋
 (6) 
𝜂(𝑅) =
𝑃𝐿
𝑃𝑅𝑋
 (7) 
𝜂 =  
𝑀2 ∙ 𝑅𝐿
(𝑅𝑅 + 𝑅𝐿)[𝑅𝑇 ∙ 𝐿𝑅 ∙ 𝐶𝑅(𝑅𝑅 + 𝑅𝐿) + 𝑀2]
 (8) 
where PR is the power delivered to the receiver circuit, PTX is the total power handled by the 
transmitter circuit, PL is the power delivered to the load and PRX is the total power handled by the 
receiver circuit. The self and mutual inductance values adopted and used in the simulation were 
derived using both Wheeler’s [26] and Grover’s [27] methods. The MATLAB model developed was 
therefore designed to comprehend: (i) the transmitter and receiver series resistance, the transmitter and 
receiver self-inductance, (ii) the transmitter-receiver inter-coil inductance, (iii) the impedance of the 
cardiac substrate (nominally modeled as a 50 Ω resistive load) and (iv) skin and proximity effects 
based on Terman [28]. 
2.3. Clinical Study 
In an initial trial of the RF defibrillator architecture developed, 30 patients with persistent AF and 
with a previous history of failed transthoracic cardioversion were recruited for a study designed  
to compare the efficacy of RF generated monophasic very-low-tilt-rectilinear versus biphasic  
very-low-tilt-rectilinear shock waveforms [20]. All necessary regulatory and ethical approvals were 
obtained and all patients who took part provided informed consent. Each patient was fully anticoagulated to 
achieve an international normalised ratio (INR) of 2 to 3 for ≥4 weeks prior to cardioversion and 
exclusion criteria were as per current guidelines. The procedures were undertaken in a cardiac 
catheterisation laboratory. After obtaining venous access, a 6F internal cardioversion catheter was 
positioned between the distal coronary sinus and right atrial appendage. The defibrillation catheter was then 
connected to the RF power receiver side of the system. Catheter placement and position was confirmed 
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via fluoroscopy in both right and left anterior oblique views (Figure 4). Intravenous midazolam was 
administered for adequate sedation prior to commencement of the cardioversion procedure. 
 
Figure 4. Position of defibrillation leads in the right atrium (RA) and coronary sinus (CS) 
for internal cardioversion of AF (right anterior oblique view). 
As part of the study protocol, patients were randomised to therapy with either a biphasic  
very-low-tilt-rectilinear (B-VLTR) 12 ms chronosymetric (6 ms/6 ms) amplitude asymmetric (negative 
phase at 50% amplitude) waveform (Figure 5a) or a 12 ms monophasic very-low-tilt-rectilinear  
(M-VLTR) waveform (Figure 5b) using a voltage step-up protocol of 50 V to 300 V in six steps  
(Table 1). Patients who failed to achieve sinus rhythm were subsequently crossed over to the opposite arm 
of the study. To minimise total procedure time, patients that failed to cardiovert for a given shock energy 
level were progressed in a timely fashion (typically <60 s) to the next shock energy level. Cardioversion 
success was therefore necessarily defined as the return of sinus rhythm for a period of >30 s. 
 
Figure 5. RF defibrillator generated very-low tilt waveforms: (a) biphasic (B-VLTR)  
12 ms chronosymmetric (6/6 ms) voltage waveform; (b) monophasic (M-VLTR) 12 ms 
waveform. 
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Table 1. Step up protocol with voltage and related shock energy (50 Ω intracardiac 
impedance assumed). 
 Study Arm 1 Biphasic Study Arm 2 Monophasic 
Step Voltage Energy (J) Voltage Energy (J) 
S1 50 0.38 50 0.60 
S2 100 1.50 100 2.40 
S3 150 3.38 150 5.40 
S4 200 6.00 200 9.60 
S5 240 8.62 240 13.80 
S6 280 11.75 280 18.81 
S7 300 18.50 300 21.60 
Post procedure, patient data was retrospectively categorised into four groups according to the type 
of shock waveform used and outcome achieved: Group-I-successful cardioversion with B-VLTR,  
Group-II-failed cardioversion with B-VLTR, Group-III-successful cardioversion using M-VLTR, and 
Group- IV-those who failed to cardiovert with M-VLTR. The primary end point was successful return 
to sinus rhythm. Associated outcome parameters analysed were leading phase voltage (V), current (I), 
energy (E), intracardiac impedance (ICI) magnitude (Z(t)), ICI variation between successive shocks (∆ZT), 
ICI magnitude across frequency (Z(f)), ICI spectro-temporal variations between successive shocks 
(∆Z(f)T) and impedance-amplitude-spectrum-area (IAMSA) across frequency. 
Time and Frequency Domain Signal Processing 
For time domain analysis dynamic variation in ICI between successive shocks (∆ZT) was 
investigated. For frequency domain analysis, the spectral content of ICI was derived using a Fast 
Fourier Transform (FFT) algorithm. Data pairs from the recorded voltage and current (as 
simultaneously captured during cardioversion) were used to derive ICI as a function of time, Z(t), for 
the first 4ms of each shock pulse waveform (excluding the rising edge for both waveform types): 
𝑍(𝑡)  =  𝑉𝑛/ 𝐼𝑛(for n =  0,1,2, . . . . N) (9) 
where Vn and In are the instantaneous voltage and current values sampled over time, respectively. To 
minimise spectral leakage a Hanning windowing (µ(t)) was applied: 
𝑍(𝑡)𝐻 = 𝑍(𝑡) × µ(𝑡) =  𝑍(𝑡) ×
1
2
(1 − cos (
2𝜋𝑡
𝑇
)) (10) 
where t, T represent the time and duration of the processed Z(t) signal segments (4 ms), respectively. 
Subsequently, an FFT was performed to determine the frequency domain function of ICI spectral 
magnitude components, Z(f), across frequency: 
𝐹𝐹𝑇(𝑘∆𝑓) =  𝑍(𝑓) =  ∑ 𝑓(𝑛∆𝑡)𝑒−𝑖(2𝜋𝑘∆𝑓)(𝑛∆𝑡)
𝑁−1
𝑛=0
(for k =  0,1,2, . . . N − 1) (11) 
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where ∆𝑡 =  𝑇/𝑁 , fS = 1/∆t = N/T, ∆f = 1/T, N is the total number of discrete points sampled,  
T represents the total sampling period, ∆𝑡 is the time interval between data points, fS represents the 
sampling frequency and ∆f is the frequency resolution of the resulting spectral plot. 
The sampling frequency was 500 kHz and the Nyquist criterion dictated that the upper frequency of 
the spectral response characteristic examined was therefore limited to 250 kHz. Based on a 4096 point 
FFT, a 4 ms sample yielded a spectral resolution of approximately 122 Hz. The magnitude spectral 
function of ICI (Z(f)) from 0–20 kHz was derived using both MS-Excel Data Analysis Package and the 
MATLAB signal processing platform, while the spectro-temporal variation of ICI within the selected 
frequency range and between successive electrical shocks (∆Z(f)T) was calculated in units of ohms and  
impedance-amplitude-spectrum-area values (IAMSA) was calculated in units of ohms-Hz (Ω-Hz). 
3. Results and Discussion 
3.1. Simulation and Experimental Characterisation 
Numerical simulations of the proposed RF transmitter-receiver architecture were undertaken as 
previously reported; using MATLAB and PSpice to evaluate several possible prototype coils for the 
application proposed [24]. Table 2 presents the self and mutual inductance values derived and used in 
the simulation for wire diameters ranging from 0.4 to 0.85 mm and also contains the calculated 
transcutaneous link efficiencies for an inter-coil separation of 25 mm with resonant frequencies from 
208 to 212 kHz both with and without the modeling of alternating current effects. 
Table 2. Self and mutual inductance values derived using Wheeler’s [26] and Grover’s [27] 
methods for wire diameters ranging from 0.40 to 0.85 mm (Tx = Rx coil diameter) and 
calculated transcutaneous link efficiency for an inter-coil separation of 25 mm with 
resonant frequencies ranging from 208 to 212 kHz both with and without the modelling of 
alternating current effects. 
Wire 
Diameter 
(mm) 
Self-Inductance 
(µH) 
[Wheeler's Method] 
Self-Inductance 
(µH) 
[Grover's Method] 
Mutual-Inductance 
(µH) 
[Grover's Method] 
0.75 
0.85 
0.40 
39.65 
38.32 
34.89 
39.08 
38.20 
34.43 
3.52 
2.93 
1.29 
Resonant 
Frequency 
(kHz) 
Tx/Rx Wire 
Diameter 
(mm) 
Tx/Rx Resonant 
Capacitor (nF) 
Estimated Link Efficiency 
with and without alternating 
current effects 
208 
211 
212 
0.85 
0.75 
0.40 
17.40/17.41 
14.89/13.57 
16.38/16.38 
0.76/0.63 
0.65/0.54 
0.12/0.10 
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The overall efficiency and stability of the RF power link in development was also modeled as a 
function of inter-coil separation. With reference to Figure 6a which plots the overall link efficiency 
versus resonant frequency for a range of inter-coil separations (5–49 mm), as expected the link 
efficiency display a typical “S” curve and is seen to be heavily dependent on the aforementioned 
parameter; where for a resonant frequency of 185 kHz an overall transfer efficiency of approximately 
60% is theoretically expected. Similarly, Figure 6b plots the gain-frequency characteristics versus 
resonant frequency for the entire system; where again it is evident that an overall gain of 
approximately −3 dB (50% power, 70% voltage) is achieved for an inter-coil separation of 
approximately 25 mm at the proposed frequency of operation (185 kHz). For comparative purposes, 
Figure 6c plots the actual link efficiency measured during testing of a number of experimental 
prototype coils versus wire diameter at an operating frequency of 185 kHz with both an  
IGBT (IRG4PH40U) and a MOSFET (IFRP260N) examined for potential use as the transmitter 
resonant tank switching device and with an approximate 52% efficiency for a wire diameter of  
0.75 mm achieved. 
 
(a) 
 
(b) 
Figure 6. Cont. 
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(c) 
Figure 6. (a) Link efficiency versus resonant frequency as a function of inter-coil 
separation; (b) gain-frequency characteristics versus resonant frequency and (c) measured 
link efficiency versus wire diameter at operating resonant frequency of 185 kHz with both 
an IGBT and a MOSFET for switching. 
Based on the preliminary simulations and experiential work undertaken, architecture sub-systems 
per Figure 1 were prototyped and fully characterized under laboratory conditions. On the transmission 
side, Figure 7 shows oscilloscope plots of the control signal from the microcontroller driving the 
power transmission resonant tank and the voltage and current waveforms that developed; where it is 
readily observed that at a switching frequency of approximately 185 kHz (T = 5.4 µs) the control signal 
(0–5 V) modulates the tank voltage and current from 0–180 V at 0–2.5 A. 
 
Figure 7. System characterisation data—TX microcontroller (VµC) control signal versus 
IGBT transistor switching voltage (VIGBT) and current (IIGBT). 
On the receiver side, Figure 8a shows the oscilloscope plot taken from the implant side rectified and 
regulated output voltagefor a load resistance (RLOAD) = 50 Ω at a frequency of 185 kHz. With reference to 
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Figure 8a, in sense mode, VRX = 15.9 V at 0.36 A (5.1 W continuous) with <8% ripple achieved. With 
reference to Figure 8b through Figure 8f, in shock mode, oscilloscope plots were taken from the 
implant side (rectified and regulated output voltage) for Tx settings of 20 V, 40 V, 60 V and 100 V, 
respectively; with a waveform tilt of <3.5% observed. Over extended testing an overall power transfer 
efficiency across a 25 mm air-skin gap of approximately 47% (worst case) was achieved. Bench 
characterisation data was therefore found to be in good agreement with both numerical calculations 
and simulation. 
3.2. Clinical Study Outcomes and Results 
As previously stated, in an initial trial of the RF defibrillator architecture developed 30 patients with 
persistent AF and with a previous history of failed transthoracic cardioversion were recruited for a study 
designed to compare the efficacy of RF generated monophonic very-low-tilt-rectilinear versus biphasic 
very-low-tilt-rectilinear shock waveforms; with the baseline characteristics of the 30 patients 
randomnised in the two arms of the study as previously reported [20]. Seven out of fifteen patients (46%) 
cardioverted to sinus rhythm with the B-VLTR protocol and 1 out of 15 patients (6%) with the M-VLTR 
protocol (P = 0.035). When the outcomes of six crossover patients were taken into account, 14 patients in 
total (46%) were restored to sinus rhythm. For the patients who were successfully treated, mean energy 
and intracardiac impedance were 8.51 J ± 3.16 J and 73.92 Ω ± 12.01 Ω, respectively. 
  
(a) (b) 
  
(c) (d) 
Figure 8. Cont. 
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(e) (f) 
Figure 8. Implant side rectified and regulated output voltage and current for inter-coil 
separation of 25 mm with RLOAD = 50 Ω at f~185 kHz: (a) in sense mode 15.9 V  
(5 V/div) at 0.32 A (5.1 W); with <8% ripple, Tx-Sense Mode = 15 V, Y-Axis: Output 
voltage (yellow) = 15.9 V / 0.32 A, (5 V/div); X-Axis: Timebase = 250 ms (25 ms/div); 
(b) Tx-Shock Mode Voltage Setting = 20 V, Y-Axis Ch-1 (green): Output voltage = 19.6 V 
(10 V/div), Y-Axis Ch-2 (red): Output current = 0.36 A (0.5 A/div); (c) Tx-Shock Mode 
Voltage Setting = 40 V, Y-Axis Ch-1 (green): Output voltage = 39.6 V (10 V/div), Y-Axis 
Ch-2 (red): Output current = 0.74 A (0.5 A/div); (d) Tx-Shock Mode Voltage Setting = 60 V, 
Y-Axis Ch-1 (green): Output voltage = 59.6 V (20 V/div), Y-Axis Ch-2 (red): Output 
current = 1.12 A (0.5 A/div); (e) Tx-Shock Mode Voltage Setting = 80 V, Y-Axis Ch-1 
(green): Output voltage = 76.8 V (20 V/div), Y-Axis Ch-2 (red): Output current = 1.48 A  
(1 A/div); (f) Tx-Shock Mode Voltage Setting = 100 V, Y-Axis Ch-1 (green): Output 
voltage = 98.4 V (20 V/div), Y-Axis Ch-2 (red): Output current = 1.9 A (1 A/div); with an 
average waveform tilt of <3.5% measured. 
3.2.1. Quantitative Time Domain Findings 
For the time domain analysis, dynamic variations of ICI between successive electrical shocks (∆ZT) 
was analyzed for statistical significance using a student t-test for all groups within the study (Table 3).  
Table 3. Dynamic changes in ICI(ZAV) between shocks measured for the B-VLTR  
and M-VLTR. 
Shock Waveform 
Group-I 
B-VLTR 
Success (N=7) 
Group-II 
B-VLTR  
Fail (N=8) 
Group-III 
M-VLTR 
Success (N=7) 
Group-IV 
M-VLTR Fail 
(N=8) 
ZAV @S1 (Ω ± SD(σ)) 79.20 ± 9.16 71.00 ± 17.55 80.50 ± 10.34 74.92 ± 22.68 
ZAV@ S2 (Ω ± SD(σ)) 76.43 ± 10.02 69.28 ± 15.02 78.22 ± 10.16 68.02 ± 22.76 
ZAV @ S3(Ω ± SD(σ)) 74.25 ± 8.59 67.70 ± 12.95 75.50 ± 9.43 66.80 ± 21.68 
|SS − ∆ZT|: S1 -> S3 
(Ω ± SD(σ)),(p-value) 
4.95 ± 2.71 
p < 0.009 
3.30 ± 5.63 
p > 0.154 
5.00 ± 1.62 
p < 0.003 
8.12 ± 6.61 
p > 0.051 
ZAV @ S4 (Ω ± SD(σ)) 74.14 ± 7.84 67.68 ± 13.32 75.54 ± 9.80 65.88 ± 20.07 
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Table 3. Cont. 
|SS - ∆ZAV|: S3 -> S4  
(Ω ± SD(σ)), (p-value) 
0.11 ± 2.04  
p > 0.147 
0.02 ± 1.61  
p > 0.891 
−0.04 ± 2.80  
p > 0.952 
0.92 ± 3.40  
p > 0.404 
ZAV @ S5 (Ω ± SD(σ)) 71.92 ± 6.46 68.86 ± 12.80 74.51 ± 9.69 66.00 ± 21.00 
|SS - ∆ZAV|: S4 -> S5  
(Ω ± SD(σ), (p-value) 
2.22 ± 1.61  
p > 0.100 
−1.18 ± 3.50  
p > 0.254 
1.03 ± 3.20  
p > 0.264 
−0.12 ± 3.35  
p > 0.775 
As is self evident, all patients who cardioverted (for both the B-VLTR and M-VTLR treatment 
protocols) exhibited a significant decrease in ICI (ZAV) between the first and third shock (Group I, III: 
SS−∆ZT(S1→S3) = 4.95 Ω (SD(σ) = 2.71 Ω), p < 0.01 and SS−∆ZT(S1→S3) = 5.00 Ω (SD(σ) = 1.62 Ω), 
p < 0.003, respectively). However, a significant decrease in ICI between successive shocks was absent 
in all patients who failed to cardiovert (Group II, IV: SS−∆ZT (S1→S3) = 3.30 Ω (SD(σ) = 5.63 Ω),  
p > 0.15 and SS−∆ZT(S1→S3) = 8.12 Ω (SD(σ) = 6.61 Ω), p > 0.05, respectively). Note that due to 
sample size for the latter pair of groups, SD(σ) values are relatively large with respect to the mean 
values rendering meaningless any attempt to assess ICI variation tendencies for SS−∆ZT(S1→S3) 
withineither of thegroups that failed to cardiovert [19]. 
3.2.2. Quantitative Frequency Domain Findings 
For frequency domain analysis, an FFT algorithm was used to derive the magnitude of the 
intracardiac impedance spectral content, Z(f) in ohms (Ω), from 0–20 kHz while dynamic variation in 
spectral content between successive electrical shocks delivered was quantified by the spectro-temporal 
parameter ∆Z(f)T and examined for statistical significance using a student t-test for all groups within 
the study. The impedance spectra for a representative patient case in each of the four clinical groups 
are presented in Figure 9a through Figure 9d. 
  
(a) (b) 
Figure 9. Cont. 
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(c) (d) 
Figure 9. FFT computed impedance magnitude (Ω) spectra for B-VLTR and M-VLTR 
shocks in the 0–20 kHz frequency range for the first three shocks (S1 -> S3) delivered to 
patients in Groups-I to IV; (a) patient PAF12, B-VLTR Impedance Amplitude Spectrum 
Area, (Ω-Hz): Group-I B-VLTR Success (0–20 kHz); (b) patient PAF18, B-VLTR 
Impedance Amplitude Spectrum Area, (Ω-Hz): Group-II B-VLTR Fail (0–20 kHz);  
(c) patient PAF14, M-VLTR Impedance Amplitude Spectrum Area, (Ω-Hz): Group-III 
M-VLTR Success (0–20 kHz); (d) patient PAF20, M-VLTR Impedance Amplitude 
Spectrum Area, (Ω-Hz): Group-IV M-VLTR Fail (0–20 kHz). 
Similar to what was observed in the time domain, frequency analysis of ICI time series, Z(t), 
revealed a relative decrease in the impedance magnitude of spectral content of the ICI from 1–20 kHz  
in all patients who successfully cardioverted. In addition, spectro-temporal variation in ICI between 
successive shocks delivered, parameter ∆Z(f)T, was also quantified in all patients cases from  
each outcome group. For this analysis, results were summarised as difference values of the  
impedance-amplitude-spectrum-area (IAMSA) between shock-1 (S1) and shock-3 (S3) (ΔIAMSA  
(S1-S3)) across various frequency ranges (Table 4). 
Table 4. ICI spectro-temporal variations of IAMSA for frequency bands and outcome groups. 
Group/IAMSA  
Value (Ω-Hz) 
Group-I and III  
(n = 15(Patients)) 
B-VLTR & M-VTLR Success 
Group-II and IV  
(n = 15 (Patients)) 
B-VLTR & M-VTLR Fail 
Shock S1 S3 S1 S3 
IAMSA(fRANGE-1) 
1 Hz–1 kHz (Ω-Hz) 
104.42 95.47 85.04 79.99 
IAMSA(fRANGE-2) 
1 kHz–10 kHz (Ω-Hz) 
8.25 2.98 4.91 1.62 
IAMSA(fRANGE-3) 
10 kHz–20 kHz (Ω-Hz) 
9.25 2.65 6.29 1.71 
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Table 4. Cont. 
IAMSA(1 Hz–20 kHz)  
(Ω-Hz) 
121.92 101.10 96.24 83.32 
ΔIAMSA: S1-S3  
1 Hz–20 kHz  
(Ω-Hz ± SD(σ), p value) 
20.82 ± 10.77 p < 0.002  
(n = 45 (waveforms)) 
12.92 ± 10.47  p< 0.030  
(n = 45 (waveforms)) 
Again, as is self evident, for both B-VLTR and M-VLTR treatment protocols, all patients who 
successfully cardioverted exhibited a significant (p < 0.01) decrease in IAMSA value measured at 
shock-1 (S1) and shock-3 (S3); ∆IAMSA(S1-S3) within the 1 Hz to 20 kHz frequency band 
(|∆(IAMSAS1-IAMSAS3)[1 Hz – 20 kHz] = 20.82 Ω-Hz (SD(σ) = 10.77 Ω-Hz), p < 0.002) versus those 
who failed to cardiovert (|∆(IAMSAS1-IAMSAS3)[1 Hz–20 kHz] = 12.92 Ω-Hz (SD(σ) = 10.47 Ω-Hz), 
p < 0.03). These heretofore unreported results are therefore indicative of prognostic attributes in both 
the time and frequency domain thatcorrelate to cardioversion outcome. 
4. Discussion 
4.1. Experimental Findings 
In this paper we propose and demonstrate a wireless powered implantable atrial defibrillator 
consisting of a battery powered hand-held radio frequency (RF) power transmitter (ex vivo) and a 
passive (battery free) implantable power-receiver (in vivo) that enables measurement of the 
intracardiac impedance (ICI) during internal atrial defibrillation. The architecture is designed to operate 
in two modes: cardiac sense mode (power-up, measure the impedance of the cardiac substrate and 
communicate data to the ex vivo power transmitter) and cardiac shock mode (delivery of a synchronised 
very-low-tilt-rectilinear electrical shock waveform). An initial prototype was implemented and tested. 
In low-power (sense) mode, >5 W was delivered across a 2.5 cm air-skin gap to facilitate measurement 
of the impedance of the cardiac substrate. In high-power (shock) mode, >180 W (delivered as a 12 ms 
monophasic very-low-tilt-rectilinear (M-VLTR) or as a 12 ms biphasic very-low-tilt-rectilinear  
(B-VLTR) chronosymmetric (6ms/6ms) amplitude asymmetric (negative phase at 50% magnitude) 
shock was reliably and repeatedly be delivered across the same interface; with >47% DC-to-DC power 
transfer at a switching frequency of 185 kHz achieved. In an initial trial of the RF architecture 
developed, 30 patients with AF were randomised to therapy with an RF generated M-VLTR or  
B-VLTR waveform using a step-up voltage protocol (50–300 V). Mean energy for successful 
cardioversion was 8.51 J ± 3.16 J. Subsequent analysis revealed that all patients who cardioverted 
exhibited a significant decrease in ICI between the first and third shocks (5.00 Ω (SD(σ) = 1.62 Ω),  
p < 0.01) while spectral analysis across frequency also revealed a significant variation in the 
impedance-amplitude-spectrum-area (IAMSA) within the same patient group (|∆(IAMSAS1-IAMSAS3) 
[1 Hz–20 kHz] = 20.82 Ω-Hz (SD(σ) = 10.77 Ω-Hz), p < 0.01); both trends being absent in all patients 
that failed to cardiovert. 
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4.2. Findings Appraisal in View of Previous Reports 
Transcutaneous Energy Transfer (TETs) or Inductive Power Transfer (IPT) technology has been 
widely investigated as a potential solution for wireless energy transfer from ex vivo to in vivo implants. 
However, a commercially viable high power TET or IPT system remains a challenging goal; 
predominately due to the localized heating of tissue that inevitably results from power losses in the 
receiver coil [29–32]. Recent publications have reported high power TET or IPT transcutaneous 
energy transfer efficiencies of up to 93% [29–35] while the transfer efficiency of our current 
implementation is closer to an average of 50% across all modes of operation. Significant additional 
work is therefore now required to model and optimise the coil winding configurations, misalignment 
tolerance, microelectronic control circuitry and rectifilter associated losses; to achieve improved 
energy transfer efficiency characteristics. Furthermore, although the power transfer requirements for 
successful cardioversion appear quite large (several hundred watts), the inherent pulsatile nature of the 
cardioversion shock waveform used (maximum 12 ms duration) effectively means that maintenance of 
local temperature rise (over baseline temperature) to <1° (in proximity to the receiver implant  
and surrounding tissue) is less problematic than in applications necessitating continuous mode  
operation [33–35]. Specifically, in the present design, continuous power is only applied for a very 
limited time during sense mode operation (typically only a few seconds is required to complete the 
‘sense’ cycle) and hence the possibility of raising the skin temperature above 42 ° (thereby resulting in 
discomfort or skin damage) has been effectively mitigated. However, significant work remains on-
going to develop a feedback control loop to automate this aspect of the design and to ensure that losses 
within the local tissue are within acceptable limits [29–35]. 
In parallel, considerable effort has also been devoted by various research teams to optimisation of 
electrical shock waveforms for internal cardioversion of AF. In particular, AF related clinical studies 
conducted at the Royal Victoria Hospital Belfast, have shown that by reducing the tilt of the 
cardioversion waveform the success and efficacy of the shock can be improved [15]. In 2008, Glover et al. 
compared the clinical efficacy of radio frequency (RF) generated low-tilt biphasic shock waveforms 
(RF B-VLTR) with standard capacitive discharge based biphasic waveforms in patients with induced 
AF during electrophysiological studies and in patients who failed to cardiovert with transthoracic 
cardioversion; thereby demonstrating the B-VTLR waveform to be more efficacious with a lower peak 
voltage required to successfully cardiovert versus a conventional biphasic capacitive discharge based 
waveform reported [16]. More recently, in 2011, Fenton et al. published a LEAP (low-energy 
antifibrillation pacing) protocol and demonstrated the successful termination of AF using sequenced 
multiple low-energy shocks; reporting that time based delivery of a train of low energy pulses could be 
used to effectively lower the cardioversion threshold to approximately 13% of the energy normally 
required for a single shock impulse with a 93% success rate in canine models [22,23]. In this work, a 
mean internal cardioversion threshold of 8.51 J ± 3.16 J was achieved using a voltage step-up protocol; 
less than half the current energy recommended for single shock internal cardioversion (20 J). Hence, 
the physiological mechanisms postulated by Fenton et al. as being potentially responsible for the 
enhanced efficacy of LEAP (shock sequencing) type protocols are thought likely to underpin the 
results observed; however, extensive theoretical and modeling will also be required to begin to 
understand the potential advantages of sequenced and step-up defibrillation protocols and the basis for 
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dynamic impedance variation as a reliable correlated marker of favorable conditions for internal 
cardioversion success. Furthermore, in this particular clinical study (which was based upon a 
sequenced step-up voltage/energy protocol) success was necessarily defined as the return of sinus 
rhythm for a period of >30 s to facilitate the rapid progression of patients (that failed to cardiovert 
when administered a given shock energy level) to the next energy level. However, it is self evident that 
further investigation of the time based evolution of the spectral content in the 1 Hz–20 kHz range  
(α (inter-cellular) and β (intra-cellular) dispersion regions) and correlation to long term clinical 
outcome (>6 months) will also be required to fully understand both the short and long termaspects of 
the complex electro-mechanical and biological physiological mechanisms at play. 
The outcomes to this study are therefore in broad agreement with previous studies and the 
advancements presented are illustrative of how wireless powered implantable devices and sensors 
capable of capturing novel electrophysiological measurements can facilitate the development of a 
better understanding and ultimately more efficient low-energy atrial defibrillation devices and 
therapies. Efficient transcutaneous power transfer and sensing of ICI during internal cardioversion are 
therefore evidenced as key to the advancement of low-energy atrial defibrillation. 
5. Conclusions 
In this paper we proposed, developed and demonstrated a wireless powered implantable atrial 
defibrillator architecture that facilitates measurement of intracardiac impedance during cardioversion. 
An initial trial of the RF architecture developed achieved a low-energy cardioversion threshold  
of 8.51 J ± 3.16 J; less than half the current energy recommended for single shock internal 
cardioversion (20 J). In addition, intracardiac impedance measurements sensed during low-energy 
cardioversion were found to contain attributes in both the time and frequency domain that correlate to 
cardioversion outcome. Efficient transcutaneous power transfer, wireless powered in vivo sensing and 
measurement of intracardiac impedance during cardioversion are therefore evidenced as key to the 
advancement of low-energy defibrillation therapies. Further development of the system and 
preparations for additional trials focusing on cardioversion waveform optimisation via capture and 
advanced analysis of the dynamic impedance spectrum of the cardiac substrate across frequency for 
multi-shock protocols and in larger patient cohorts remain on-going. 
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